Evommune EVMN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$6.99M-920% | $852.32K+229% | $259K— | —— | -$126.78K+54.4% | ||
| $4.58K-2.7% | $4.71K— | —— | —— | $6.23K-20.1% | ||
| $123.29K— | —— | —— | —— | $252.91K+144% | ||
| -$424.56K+84.6% | -$2.75M— | —— | —— | $175.99K+213% | ||
| $150.6K-49.6% | $298.86K0.0% | $298.86K0.0% | $298.86K0.0% | $298.86K— | ||
| —— | $24.93K0.0% | $24.93K0.0% | $24.93K-49.1% | $48.95K-47.9% | ||
| $897+4.4% | $859— | —— | —— | $894+6.0% | ||
| -$1.22M-127% | $4.47M— | —— | —— | -$174K-83.8% | ||
| -$1.65M-196% | $1.72M— | —— | —— | $1.99K+105% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Evommune generate?
- Evommune (EVMN) generated -$2.9M in operating cash flow over the trailing twelve months.
- Where does Evommune 's cash flow data come from?
- Every line is extracted from Evommune 's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
